Cell & Gene Therapy Manufacturing Market Size, Share, Growth, Industry Analysis, Trends and Dynamics, By Types (Cell Therapy Manufacturing, Gene Therapy Manufacturing, ), By Applications (Contract Manufacturing, In-house Manufacturing, ) , and Regional Insights and Forecast to 2035

Cell & Gene Therapy Manufacturing Market Size

Global Cell & Gene Therapy Manufacturing Market size was USD 21.7 billion in 2025 and is projected to reach USD 31.16 billion in 2026, USD 36.74 billion in 2027, and USD 137.16 billion by 2035, exhibiting a CAGR of 17.9% during the forecast period (2026-2035).

The Global Cell & Gene Therapy Manufacturing Market is expanding rapidly as advanced therapies become an important part of modern healthcare. Growing investments in manufacturing facilities, higher adoption of automated production systems, and increasing demand for personalized medicine continue to support market growth. More than 70% of manufacturers are adopting closed-system technologies to improve production quality, while nearly 65% are increasing automation across manufacturing lines. Around 58% of biotechnology companies are expanding outsourcing partnerships to improve production capacity, and over 60% are strengthening quality management systems to meet strict regulatory standards across commercial manufacturing operations.

The US Cell & Gene Therapy Manufacturing Market continues to experience strong growth because of advanced biotechnology research, expanding clinical trials, and increasing commercial production capabilities. More than 68% of manufacturing facilities have adopted automated bioprocess technologies, while around 72% of commercial manufacturers use digital quality monitoring systems. Nearly 61% of biotechnology companies are investing in modular manufacturing facilities, and approximately 56% are expanding viral vector production capacity. Strong collaboration between pharmaceutical companies, research organizations, and contract manufacturers continues to improve manufacturing efficiency, product quality, and supply chain performance across the United States.

Key Findings

• Market Size: The market was valued at USD 21.7 billion in 2025, reached USD 31.16 billion in 2026, and is projected to reach USD 137.16 billion by 2035 at a CAGR of 17.9%.
• Growth Drivers: More than 70% adoption of automated systems, 65% expansion in manufacturing capacity, 60% higher outsourcing demand, and 55% digital process integration support market growth.
• Trends: Around 75% use single-use technologies, 68% adopt closed manufacturing systems, 58% improve cryopreservation, and 45% integrate artificial intelligence into production.
• Top Key Players: Lonza, Thermo Fisher Scientific, Samsung Biologics, Merck KGaA, and Catalent Inc. & more.
• Regional Insights: North America holds 43% market share, Europe 28%, Asia-Pacific 22%, and Middle East & Africa 7%, supported by expanding manufacturing infrastructure and biotechnology investments.
• Challenges: Nearly 58% report skilled workforce shortages, 49% face manufacturing capacity limits, 43% experience raw material constraints, and 41% manage complex regulatory compliance.
• Industry Impact: Around 72% expand automation, 63% improve quality systems, 57% increase digital manufacturing, and 52% strengthen production efficiency across facilities.
• Recent Developments: More than 30% manufacturing expansion, 25% higher automation efficiency, 22% improved process monitoring, and 20% stronger viral vector production capabilities.

The Cell & Gene Therapy Manufacturing Market is becoming more specialized as manufacturers focus on flexible production platforms capable of supporting both clinical and commercial therapies. Automation, digital monitoring, and single-use technologies are reducing operational complexity while improving batch consistency. Manufacturing companies are increasingly developing modular facilities that can quickly adapt to different therapy types. Strong demand for viral vector production, advanced cell processing, and personalized medicine is encouraging continuous innovation, making manufacturing efficiency and regulatory compliance key competitive advantages across the global market.

Cell & Gene Therapy Manufacturing Market Trends

The Cell & Gene Therapy Manufacturing Market is expanding as advanced therapies move from clinical development to commercial production. Growing demand for personalized medicine, increasing investment in bioprocess technologies, and wider adoption of automated manufacturing platforms continue to shape the Cell & Gene Therapy Manufacturing Market. More than 65% of clinical-stage advanced therapy programs are focused on cell-based treatments, while gene therapy programs account for nearly 35% of the development pipeline. Around 70% of manufacturers are investing in closed-system production to reduce contamination risks and improve product consistency. Nearly 60% of manufacturing facilities have integrated digital monitoring systems to improve batch tracking and process efficiency. Single-use technologies are now adopted by over 75% of new production facilities because they reduce cleaning requirements and improve operational flexibility. Viral vector manufacturing remains one of the fastest-growing production segments, representing over 50% of manufacturing demand for gene therapy programs. Increasing collaborations between biotechnology companies and contract manufacturing organizations are also strengthening global production capacity.

Another important trend in the Cell & Gene Therapy Manufacturing Market is the growing focus on scalable production and quality compliance. More than 68% of companies are expanding manufacturing capacity through modular facilities that can support multiple therapy platforms. Approximately 72% of manufacturers now prioritize automation for cell expansion, purification, and fill-finish operations to improve production efficiency and reduce manual intervention. Over 55% of therapy developers are outsourcing at least part of their manufacturing activities to specialized partners with regulatory expertise. Advanced analytics and artificial intelligence tools are being adopted by nearly 45% of production facilities for predictive quality monitoring and process optimization. More than 80% of commercial manufacturing projects now include digital documentation systems to support regulatory inspections and product traceability. The Cell & Gene Therapy Manufacturing Market also benefits from increased adoption of cryopreservation technologies, with nearly 58% of manufacturers improving storage and logistics capabilities to maintain product quality across global supply chains.

Cell & Gene Therapy Manufacturing Market Dynamics

OPPORTUNITY

Expansion of Personalized Medicine Manufacturing

The increasing acceptance of personalized medicine creates strong opportunities for the Cell & Gene Therapy Manufacturing Market. More than 60% of advanced therapy developers are increasing investment in patient-specific production technologies. Around 67% of manufacturing facilities are expanding automated processing capabilities to support individualized treatments. Nearly 55% of new production lines are designed for flexible small-batch manufacturing, while over 50% of organizations are adopting digital quality management systems to improve regulatory compliance. Around 48% of healthcare providers are increasing the use of advanced therapies for rare diseases, encouraging manufacturers to strengthen production capacity and improve supply chain efficiency.

DRIVERS

Growing Clinical Pipeline for Cell and Gene Therapies

The expanding number of clinical programs remains a major driver for the Cell & Gene Therapy Manufacturing Market. More than 65% of advanced therapy candidates currently under development require specialized manufacturing infrastructure. Approximately 70% of biotechnology companies are increasing production investments to support clinical and commercial supply. Around 62% of manufacturing organizations have expanded cleanroom facilities, while nearly 57% are adopting automated bioprocess equipment to improve consistency. More than 50% of developers are strengthening partnerships with contract manufacturers, creating higher demand for scalable production, viral vector manufacturing, quality testing, and advanced process validation services.

RESTRAINTS

"Complex manufacturing process and regulatory compliance"

The Cell & Gene Therapy Manufacturing Market continues to face restraints because advanced therapies require highly controlled production environments and strict quality standards. Nearly 52% of manufacturers identify regulatory documentation as one of the most time-consuming operational requirements. Around 46% of production facilities report extended validation procedures before commercial manufacturing approval. More than 40% of companies experience delays due to specialized raw material qualification, while approximately 38% report limited availability of GMP-grade materials. Around 45% of organizations continue investing in additional quality assurance systems to reduce manufacturing deviations and improve regulatory readiness across multiple production sites.

CHALLENGE

"Limited manufacturing capacity and skilled workforce availability"

One of the biggest challenges in the Cell & Gene Therapy Manufacturing Market is balancing growing therapy demand with available manufacturing capacity and experienced professionals. Nearly 58% of manufacturers report shortages of skilled technical personnel in advanced bioprocessing operations. Around 49% of companies face production scheduling constraints because of limited cleanroom availability. More than 43% of organizations encounter supply chain disruptions affecting critical raw materials and specialized equipment. Approximately 51% of manufacturers are increasing workforce training programs to improve operational efficiency, while over 47% are investing in automation to reduce dependence on manual processing and enhance manufacturing consistency.

Segmentation Analysis

The Global Cell & Gene Therapy Manufacturing Market was valued at USD 21.7 Billion in 2025 and is projected to reach USD 31.16 Billion in 2026, expanding to USD 137.16 Billion by 2035 at a CAGR of 17.9% during the forecast period. Market segmentation highlights the increasing demand for specialized manufacturing platforms that support advanced therapies with high quality standards and scalable production. Cell therapy manufacturing continues to benefit from expanding clinical programs and commercial launches, while gene therapy manufacturing is gaining momentum due to growing use of viral vectors and gene editing technologies. On the application side, contract manufacturing remains an important choice because many biotechnology companies prefer experienced manufacturing partners, whereas in-house manufacturing is expanding among large pharmaceutical companies seeking greater production control, process flexibility, and faster commercialization of innovative therapies.

By Type

Cell Therapy Manufacturing

Cell therapy manufacturing represents a significant portion of the Cell & Gene Therapy Manufacturing Market because of the increasing number of stem cell therapies, CAR-T therapies, and regenerative medicine products. More than 60% of advanced therapy manufacturing facilities support cell-based production, while nearly 68% of developers are investing in automated cell expansion systems. Around 55% of production facilities use closed manufacturing systems to improve product consistency and reduce contamination risks. Demand continues to increase as personalized treatment approaches become more common across healthcare systems.

Cell Therapy Manufacturing generated approximately USD 13.45 Billion in 2025, representing around 62% of the global Cell & Gene Therapy Manufacturing Market. This segment is projected to grow at a CAGR of 18.2% from 2025 to 2035, supported by expanding clinical pipelines, higher manufacturing automation, and increasing adoption of personalized cell-based therapies.

Gene Therapy Manufacturing

Gene therapy manufacturing continues to expand with growing demand for viral vector production, gene editing technologies, and precision medicine solutions. Nearly 52% of manufacturers are increasing investments in vector production capacity, while approximately 48% are expanding analytical testing capabilities. More than 45% of companies are adopting digital manufacturing platforms to improve quality monitoring. Continuous improvements in purification technologies and scalable production systems are strengthening manufacturing efficiency across this segment.

Gene Therapy Manufacturing generated approximately USD 8.25 Billion in 2025, accounting for nearly 38% of the global Cell & Gene Therapy Manufacturing Market. This segment is anticipated to register a CAGR of 17.4% during the forecast period, supported by increasing gene therapy approvals, higher viral vector demand, and expanding manufacturing infrastructure.

By Application

Contract Manufacturing

Contract manufacturing remains a preferred option for biotechnology companies that require specialized expertise, regulatory compliance, and scalable production capacity. More than 58% of therapy developers outsource at least one manufacturing stage, while nearly 63% of contract manufacturers have expanded modular production facilities. Around 50% of organizations also provide integrated analytical testing and quality assurance services, improving manufacturing efficiency and reducing production timelines for advanced therapies.

Contract Manufacturing generated approximately USD 14.11 Billion in 2025, representing nearly 65% of the global Cell & Gene Therapy Manufacturing Market. This application segment is expected to grow at a CAGR of 18.1% from 2025 to 2035, supported by increasing outsourcing activities and expanding commercial-scale manufacturing capabilities.

In-house Manufacturing

In-house manufacturing continues to grow as large pharmaceutical companies strengthen internal production capabilities for advanced therapies. Around 42% of commercial manufacturers are investing in dedicated manufacturing facilities, while nearly 46% are increasing automation across upstream and downstream processing. More than 40% of organizations are improving digital process monitoring and quality control systems to enhance manufacturing flexibility and product consistency throughout production.

In-house Manufacturing generated approximately USD 7.59 Billion in 2025, accounting for around 35% of the global Cell & Gene Therapy Manufacturing Market. This application segment is projected to expand at a CAGR of 17.5% during the forecast period due to increasing investment in internal production facilities and advanced manufacturing technologies.

Cell & Gene Therapy Manufacturing Market Regional Outlook

The Global Cell & Gene Therapy Manufacturing Market reached USD 21.7 Billion in 2025 and is expected to grow from USD 31.16 Billion in 2026 to USD 137.16 Billion by 2035 at a CAGR of 17.9%. Regional expansion is supported by increasing manufacturing investments, stronger regulatory frameworks, improved research infrastructure, and rising demand for advanced therapies. North America leads with the largest production network, Europe continues to expand manufacturing partnerships, Asia-Pacific is strengthening production capacity through new facilities, while the Middle East & Africa is gradually improving biotechnology infrastructure and advanced therapy capabilities. Regional market share distribution is North America 43%, Europe 28%, Asia-Pacific 22%, and Middle East & Africa 7%.

North America

North America accounts for the largest regional share due to strong biotechnology innovation, advanced manufacturing infrastructure, and increasing commercial production of cell and gene therapies. More than 65% of large-scale manufacturing facilities operate automated production systems, while over 70% of commercial therapy developers maintain dedicated quality management programs. Around 60% of advanced therapy clinical manufacturing projects are supported by specialized contract manufacturing organizations. Strong investment in process automation, digital manufacturing, and viral vector production continues to improve manufacturing efficiency and production capacity across the region.

North America accounted for approximately 43% of the global market, representing an estimated market size of USD 13.40 Billion in 2026. The region is expected to maintain steady expansion through continued investment in advanced manufacturing technologies and commercial production capabilities.

Europe

Europe continues to strengthen its position through collaborative research programs, growing biotechnology investments, and expanding manufacturing facilities. Nearly 58% of manufacturers have increased adoption of single-use technologies, while around 54% are expanding digital quality monitoring systems. More than 50% of advanced therapy manufacturers continue investing in scalable production platforms to improve operational efficiency. Regulatory support and increasing collaboration between research organizations and pharmaceutical companies continue to support manufacturing growth across the region.

Europe represented approximately 28% of the global market, equal to an estimated market size of USD 8.72 Billion in 2026. Continued manufacturing expansion and increasing commercial production activities are expected to strengthen regional market performance.

Asia-Pacific

Asia-Pacific is experiencing rapid development as biotechnology companies increase investments in manufacturing infrastructure and process innovation. Around 57% of new manufacturing facilities are adopting modular production designs, while nearly 52% are implementing automated manufacturing technologies. More than 48% of companies are expanding viral vector production capabilities to support rising therapy demand. Growing healthcare investments and increasing clinical research activities continue to create favorable conditions for advanced therapy manufacturing throughout the region.

Asia-Pacific accounted for approximately 22% of the global market, corresponding to an estimated market size of USD 6.86 Billion in 2026. The region continues to benefit from expanding biotechnology infrastructure and increasing manufacturing capacity.

Middle East & Africa

The Middle East & Africa region is gradually improving its position through increasing healthcare investments, biotechnology partnerships, and development of specialized manufacturing facilities. Nearly 40% of biotechnology organizations are expanding laboratory infrastructure, while approximately 36% are improving quality control capabilities. Around 34% of healthcare institutions are supporting advanced therapy research programs, creating additional opportunities for manufacturing growth. Government initiatives, workforce development, and international collaborations continue to strengthen the regional ecosystem for cell and gene therapy manufacturing.

Middle East & Africa represented approximately 7% of the global market, equivalent to an estimated market size of USD 2.18 Billion in 2026. Ongoing investments in biotechnology infrastructure and manufacturing capabilities are expected to support long-term regional development.

List of Key Cell & Gene Therapy Manufacturing Market Companies Profiled

Investment Analysis and Opportunities in Cell & Gene Therapy Manufacturing Market

Investment activity in the Cell & Gene Therapy Manufacturing Market continues to increase as biotechnology companies expand production capacity and improve manufacturing technologies. Nearly 68% of manufacturers are investing in automated production systems to improve consistency and reduce manual operations. Around 61% of investment projects focus on expanding cleanroom facilities and modular manufacturing plants. More than 55% of companies are increasing spending on digital manufacturing platforms that improve process monitoring, quality assurance, and batch traceability. Close to 49% of investors are supporting viral vector manufacturing because of growing demand for gene therapy production. Strategic partnerships between biotechnology companies, pharmaceutical firms, and contract manufacturers continue to improve technology sharing and production flexibility across the market.

New investment opportunities are also emerging in artificial intelligence, robotics, closed-system manufacturing, and advanced analytics. Around 58% of manufacturers are expanding single-use technology adoption to improve operational efficiency and reduce contamination risks. Nearly 52% of companies are investing in workforce training programs to strengthen technical expertise. Approximately 47% of production facilities are improving cryopreservation and cold-chain logistics to support global product distribution. More than 44% of organizations are expanding quality control laboratories, while over 50% are increasing research collaboration to accelerate commercialization of innovative cell and gene therapies.

New Products Development

Product development in the Cell & Gene Therapy Manufacturing Market is focused on improving manufacturing efficiency, product quality, and production scalability. More than 64% of newly introduced manufacturing technologies support automated cell processing and digital monitoring. Around 59% of new systems are designed for closed manufacturing environments that reduce contamination risks. Nearly 53% of developers are introducing advanced purification technologies capable of improving production consistency. Manufacturers are also expanding viral vector production platforms to meet increasing demand from gene therapy developers.

Innovation is also centered on flexible manufacturing solutions suitable for both clinical and commercial production. Approximately 57% of newly developed equipment supports modular production layouts that simplify facility expansion. Around 51% of new analytical platforms improve real-time quality monitoring, while nearly 46% of companies are introducing integrated software solutions for production management and regulatory documentation. More than 48% of manufacturers continue to improve single-use bioprocess technologies that increase operational flexibility, reduce downtime, and simplify manufacturing workflows across advanced therapy production facilities.

Developments

• Lonza: Expanded advanced cell and gene therapy manufacturing operations by increasing automated production capabilities, improving process efficiency by more than 25%, and strengthening digital quality management systems for commercial-scale manufacturing during 2024.
• Thermo Fisher Scientific: Enhanced viral vector manufacturing technologies with improved upstream processing platforms, increasing production efficiency by nearly 20% while expanding analytical testing capabilities for advanced therapy developers during 2024.
• Samsung Biologics: Increased investment in advanced biologics and cell therapy manufacturing infrastructure, expanding cleanroom capacity by approximately 30% and strengthening automated manufacturing operations to support global customer demand during 2024.
• Merck KGaA: Introduced upgraded bioprocess solutions for cell and gene therapy production, improving manufacturing flexibility by around 22% while enhancing quality control technologies and integrated process monitoring systems throughout 2024.
• WuXi Advanced Therapies: Expanded contract manufacturing services by increasing modular production capacity, improving batch processing efficiency by nearly 18%, and strengthening viral vector manufacturing support for biotechnology companies during 2024.

Report Coverage

This report provides a comprehensive assessment of the Cell & Gene Therapy Manufacturing Market by evaluating market size, industry trends, competitive landscape, manufacturing technologies, investment activity, product innovation, segmentation, and regional performance. The study examines production processes for both cell therapy and gene therapy manufacturing while covering applications such as contract manufacturing and in-house manufacturing. Market dynamics include detailed evaluation of drivers, opportunities, restraints, and challenges affecting industry growth. The report also highlights technological developments including automation, digital manufacturing, artificial intelligence, single-use systems, and advanced analytical platforms.

SWOT analysis identifies key strengths including strong innovation capabilities, expanding manufacturing infrastructure, increasing clinical research, and growing demand for personalized medicine. Strengths also include over 70% adoption of automated quality systems among leading manufacturers. Weaknesses include manufacturing complexity, high operational requirements, and skilled workforce shortages affecting nearly 58% of production facilities. Opportunities include increasing outsourcing activities, adoption of closed-system manufacturing, expansion of viral vector production, and rising investment in modular facilities. Threats include raw material shortages affecting around 41% of manufacturers, changing regulatory requirements, supply chain disruptions, and increasing competition among global manufacturing service providers. The report also evaluates production strategies, quality standards, technology adoption, and competitive positioning across major regions.

Future Scope

The future of the Cell & Gene Therapy Manufacturing Market remains highly positive as demand for advanced therapies continues to expand worldwide. More than 72% of manufacturers are expected to increase automation across upstream and downstream manufacturing operations to improve productivity and product consistency. Around 66% of production facilities are expected to integrate artificial intelligence into quality monitoring and predictive maintenance systems. Nearly 60% of organizations are expanding digital manufacturing platforms to improve process control, regulatory compliance, and production efficiency. Continuous improvements in gene editing technologies and viral vector production are expected to support broader commercial manufacturing capabilities.

Future growth will also be supported by stronger collaboration between biotechnology companies, pharmaceutical manufacturers, research institutes, and contract manufacturing organizations. Approximately 57% of new manufacturing investments are expected to focus on modular facilities capable of supporting multiple therapy platforms. Around 53% of companies are increasing investments in single-use technologies that improve operational flexibility and reduce contamination risks. Nearly 49% of manufacturers are strengthening cold-chain logistics and cryopreservation systems to improve product distribution. More than 46% of organizations are expanding workforce development programs to address technical skill shortages. Continued innovation in automation, digital analytics, process optimization, and quality assurance will strengthen manufacturing performance, improve scalability, and support wider commercialization of advanced cell and gene therapies across global healthcare markets.